VGXI Announces Strategic Multi-Year Partnership with Resilience to Accelerate Biomanufacturing of Advanced Medicines
Under this new partnership, VGXI will serve as a trusted plasmid DNA manufacturer to support Resilience's advanced therapy…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
25 Jan 24
Under this new partnership, VGXI will serve as a trusted plasmid DNA manufacturer to support Resilience's advanced therapy…
25 Jan 24
New developments in the biopharmaceutical field fuel a need for highly scalable and flexible solutions
24 Jan 24
Inhibrx shareholders will receive $30 per share in cash, a CVR that can be exchanged for $5, plus…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
24 Jan 24
Obese participants, who were administered with up to 30mg oral ecnoglutide once-daily for six weeks, achieved a mean…
24 Jan 24
OpCT-001 is the lead cell therapy candidate being developed under the strategic R&D agreement that was formed in…
24 Jan 24
Under the partnership, both entities will use GenEdit's NanoGalaxy platform to explore and advance innovative nanoparticles, facilitating the…
24 Jan 24
Zynrelef is a dual-acting local anaesthetic, created to provide a fixed-dose combination of the local anaesthetic bupivacaine and…
24 Jan 24
Under the collaboration, Celltrion will delegate WuXi XDC as primary service provider on each of the integrated projects,…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
24 Jan 24
Clinical stage company formed from the merger of Oxitope Pharma and Arxx Therapeutics
23 Jan 24
NS-229 is a potent and selective Janus kinase (JAK) 1 inhibitor, being developed to treat EGPA by restraining…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates